The IsoFlux system (Fluxion Biosciences, Inc., Alameda, CA, USA) is a semi-automated platform that enriches circulating tumor cells (CTCs) by combining EpCAM-based immunomagnetic positive selection with microfluidic technology, similar to the FDA-approved CellSearch system. This evidence concerns the gene EPCAM and neoplasm.